| First Author | Lança T | Year | 2013 |
| Journal | J Immunol | Volume | 190 |
| Issue | 12 | Pages | 6673-80 |
| PubMed ID | 23686489 | Mgi Jnum | J:204841 |
| Mgi Id | MGI:5543546 | Doi | 10.4049/jimmunol.1300434 |
| Citation | Lanca T, et al. (2013) Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic gammadelta T lymphocytes to tumor beds. J Immunol 190(12):6673-80 |
| abstractText | Tumor-infiltrating lymphocytes (TILs) are important prognostic factors in cancer progression and key players in cancer immunotherapy. Although gammadelta T lymphocytes can target a diversity of tumor cell types, their clinical manipulation is hampered by our limited knowledge of the molecular cues that determine gammadelta T cell migration toward tumors in vivo. In this study we set out to identify the chemotactic signals that orchestrate tumor infiltration by gammadelta T cells. We have used the preclinical transplantable B16 melanoma model to profile chemokines in tumor lesions and assess their impact on gammadelta TIL recruitment in vivo. We show that the inflammatory chemokine CCL2 and its receptor CCR2 are necessary for the accumulation of gammadelta TILs in B16 lesions, where they produce IFN-gamma and display potent cytotoxic functions. Moreover, CCL2 directed gammadelta T cell migration in vitro toward tumor extracts, which was abrogated by anti-CCL2 neutralizing Abs. Strikingly, the lack of gammadelta TILs in TCRdelta-deficient but also in CCR2-deficient mice enhanced tumor growth in vivo, thus revealing an unanticipated protective role for CCR2/CCL2 through the recruitment of gammadelta T cells. Importantly, we demonstrate that human Vdelta1 T cells, but not their Vdelta2 counterparts, express CCR2 and migrate to CCL2, whose expression is strongly deregulated in multiple human tumors of diverse origin, such as lung, prostate, liver, or breast cancer. This work identifies a novel protective role for CCL2/CCR2 in the tumor microenvironment, while opening new perspectives for modulation of human Vdelta1 T cells in cancer immunotherapy. |
